TENX — Tenax Therapeutics Share News
0.000.00%
Last trade - 00:00Tenax Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Tenax Therapeutics Inc expected to post a loss of $8.14 a share - Earnings Preview
Brief: Tenax Therapeutics Says On Feb 22 It Got Nasdaq Notification Confirming That Co Regained Compliance With Minimum Float Requirement, Matter Is Closed
Brief: Tenax Therapeutics Announces Global License Amendment That Expands Rights To Levosimendan
Brief: CVI Investments, Inc. Reports 9.9% Passive Stake In Tenax Therapeutics Inc As Of Feb 8, 2024 - SEC Filing
Brief: Tenax Therapeutics Announces Pricing Of Approximately $9 Million Public Offering
Brief: Tenax Therapeutics Forecasts Topline Level Data Will Be Available Second Half Of 2025
U.S. STOCKS ON THE MOVE-Adobe, United Parcel Service, ZeroFox Holdings
U.S. STOCKS ON THE MOVE-New York Community Bancorp, Rallybio, Willis Towers Watson
Tenax jumps after receiving additional patents for heart disease drug
Brief: Tenax Therapeutics Announces USPTO Grants Notice Of Allowance For U.S. Patent Application
Brief: Tenax Therapeutics Announces Reverse Stock Split
Brief: Tenax Therapeutics Announces Professor Javed Butler Joins Ph-Hfpef Scientific Advisory Board
Tenax soars after FDA clears heart failure drug for late-stage trial
Tenax soars after FDA clears heart failure drug for late-stage trial
Brief: Tenax Therapeutics Announces FDA Clearance Of Ind For Tnx-103 (Oral Levosimendan)
U.S. STOCKS ON THE MOVE-HP, Digital World Acquisition, Guardant Health
Brief: Tenax Therapeutics Got Nasdaq Notice Granting Request For Extension Through March 25, 2024 To Evidence Compliance Minimum Bid Price Requirement
Tenax Therapeutics Inc reports results for the quarter ended in June - Earnings Summary